ロード中...
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel
BACKGROUND: Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3541348/ https://ncbi.nlm.nih.gov/pubmed/23194409 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1757-2215-5-40 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|